NOT KNOWN FACTUAL STATEMENTS ABOUT MBL77

For sufferers with symptomatic illness necessitating therapy, ibrutinib is often advisable depending on 4 stage III randomized scientific trials comparing ibrutinib with chlorambucil monotherapy106 together with other generally used CIT combos, namely FCR, bendamustine furthermore rituximab and chlorambucil as well as obinutuzumab (ClbO).107–109